1. 186 AZACITIDINE IS EFFICACIOUS IN CHRONIC MYELOMONOCYTIC LEUKEMIA INVOLVING SKIN AND MUCOSA. Issue 1 (April 2015) Authors: Di Battista, V.; Matteucci, C.; Quintini, M.; Ballanti, S.; Falini, B.; Mecucci, C. Journal: Leukemia research Issue: Volume 39:Issue 1(2015:Jan.) Page Start: S93 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. EBV LEAVES ITS MARK: NEW EVIDENCE OF <<HIT AND RUN>> HYPOTHESIS IN B‐CELL LYMPHOMAS FROM NON‐CONVENTIONAL METHODS. (12th June 2019) Authors: Mundo, L.; Ambrosio, M.R.; Del Porro, L.; Granai, M.; Mancini, V.; Schiavoni, G.; Anagnostopoulos, I.; Falini, B.; Lazzi, S.; Tiacci, E.; Leoncini, L. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 529 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FRI0001 IL-17 producing-DN T cells are expanded in the blood, infiltrate salivary glands and are resistant to corticosteroids in sjÖgren's syndrome. (23rd January 2014) Authors: Alunno, A.; Bistoni, O.; Bartoloni, E.; Caterbi, S.; Bigerna, B.; Tabarrini, A.; Mannucci, R.; Beghelli, D.; Falini, B.; Gerli, R. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 311 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Induction of the pro-myelocytic leukaemia gene by type I and type II interferons. Issue 5 (1998) Authors: Heuser, M.; van der Kuip, H.; Falini, B.; Peschel, C.; Huber, C.; Fischer, T. Journal: Mediators of inflammation Issue: Volume 7:Issue 5(1998) Page Start: 319 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P1144: RADIOIMMUNOTHERAPY (RIT) VERSUS AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION (ASCT) IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA: A FONDAZIONE ITALIANA LINFOMI (FIL) PHASE III TRIAL. (23rd June 2022) Authors: Ladetto, M.; Tavarozzi, R.; Evangelista, A.; Zanni, M.; Tucci, A.; Anastasia, A.; Botto, B.; Boccomini, C.; Bolis, S.; Volpetti, S.; Zilioli, V. R.; Puccini, B.; Arcari, A.; Pavone, V.; Gaidano, G.; Corradini, P.; Tani, M.; Ferrero, S.; Cavallo, F.; Milone, G. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1032 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P574: CPX-351 COMBINED WITH HEMATOPOIETIC CELL TRANSPLANTATION WITH REGULATORY AND CONVENTIONAL T CELL IMMUNOTHERAPY FOR HIGH-RISK ACUTE MYELOID LEUKEMIA. (23rd June 2022) Authors: Sciabolacci, S.; Ruggeri, L.; Cardinali, V.; Brunetti, L.; Tricarico, S.; Saldi, S.; Marzuttini, F.; Griselli, M.; Perta, G.; Viglione, V.; Cimino, G.; Osmani, A.; Caridi, M.; Sembenico, R.; Terenzi, A.; Zei, T.; Iacucci Ostini, R.; Martelli, M. F.; Falini, B.; Velardi, A. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 473 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. PO-1174 Radiation therapy as bridging strategy before infusion of CAR T in non hodgkin lymphoma patients. (May 2022) Authors: Saldi, S.; Perriello, V.; Falini, L.; Ingrosso, G.; Zucchetti, C.; Fulcheri, C.P.L.; Di Pilato, A.C.; Camilli, F.; Falini, B.; Aristei, C. Journal: Radiotherapy and oncology Issue: Volume 170(2022)Supplement 1 Page Start: S995 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. S139: BCOR DELETION SUSTAINS NOTCH1 SIGNALLING ACTIVATION TO ACCELERATE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PROGRESSION TOWARD RICHTER TRANSFORMATION IN MICE. (23rd June 2022) Authors: Rompietti, C.; Sorcini, D.; De Falco, F.; Dorillo, E.; Adamo, F. M.; Silva Barcelos, E. C.; Stella, A.; Scialdone, A.; Esposito, A.; Arcaleni, R.; Bigerna, B.; Martino, G.; Moretti, L.; Mameli, M. G.; Geraci, C.; Sandoletti, L.; Cipiciani, A.; Rosati, E.; Falini, B.; Sportoletti, P. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 40 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. THE BRAF INHIBITOR VEMURAFENIB PLUS RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE RESPONSES IN RELAPSED/REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE‐2 TRIAL. (12th June 2019) Authors: Tiacci, E.; De Carolis, L.; Simonetti, E.; Zaja, F.; Capponi, M.; Ambrosetti, A.; Lucia, E.; Antolino, A.; Pulsoni, A.; Ferrari, S.; Zinzani, P.; Rigacci, L.; Gaidano, G.; Della Seta, R.; Frattarelli, N.; Falcucci, P.; Visani, G.; Foà, R.; Falini, B. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 110 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗